Mal-PEG2-VCP-Eribulin
| Code | Size | Price |
|---|
| TAR-T18278-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T18278-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].
CAS:
2130869-18-8
Molecular Weight:
1374.57
Purity:
0.98
SMILES:
C=C1C[C@@]2(CC[C@@]34O[C@@]5([C@]6([C@]([C@@](O3)([C@@](C4)(O6)[H])[H])(O[C@@]7([C@@]5(O[C@](CC7)(CC(=O)C[C@]8([C@@](O[C@H](C[C@@H](CNC(OCC9=CC=C(NC([C@@H](NC([C@@H](NC(CCOCCOCCN%10C(=O)C=CC%10=O)=O)[C@@H](C)C)=O)CCCNC(N)=O)=O)C=C9)=O)O)[C@@H]8OC)(C[C@]%11(O[C@@](CC[C@@]1(O2)[H])(C[C@@H](C)C%11=C)[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H]
References
Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.
Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.